LAVAL, QC, Aug. 2 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that James Howard-Tripp, Chief Executive Officer of the Company will present at the 27th Annual Canaccord Adams Global Growth Conference in Boston, on Thursday, August 9, 2007 at 11:30 a.m. ET.
Interested parties may access the live webcast by visiting the “Events” section of the homepage of the Company’s website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.
The Conference, which is one of the longest running institutional events focused exclusively on growth companies, will include 270 public and private companies.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company’s lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company has a robust pipeline of follow-on products in both pre-clinical and clinical development. For more information, please visit www.labopharm.com
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Company’s products thereafter, if they are approved. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: At Labopharm, Mark A. D’Souza, Chief Financial Officer, Tel:(450) 686-0207; At The Equicom Group, Jason Hogan, Media and InvestorRelations, Tel: (416) 815-0700, jhogan@equicomgroup.com; French: EricBouchard, Tel: (514) 844-7997, ebouchard@equicomgroup.com
